Nanopublications

Matches in Nanopublications for { ?s ?p "[None (0/22) of normal cervical biopsies, 9% (6/66) of CIN1 lesions, 53% (34/64) of CIN3 lesions, 90% (85/94) of cervical squamous cell carcinomas (SCCs), and 93% (26/28) of cervical adenocarcinomas (AdCAs) demonstrated MAL promoter methylation at both promoter regions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

Showing items 1 to 10 of 10 with 100 items per page.

NP212371.RAB64zRHwq5rnDpR3EKjdnWOA3h_8hLuH1rzI9PRE2rTU130_assertion description "[None (0/22) of normal cervical biopsies, 9% (6/66) of CIN1 lesions, 53% (34/64) of CIN3 lesions, 90% (85/94) of cervical squamous cell carcinomas (SCCs), and 93% (26/28) of cervical adenocarcinomas (AdCAs) demonstrated MAL promoter methylation at both promoter regions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP212371.RAB64zRHwq5rnDpR3EKjdnWOA3h_8hLuH1rzI9PRE2rTU130_provenance.
NP829095.RAStaN5AjefHaBCHrklV1m6oegr9ACmqIjlZrm36A4c04130_assertion description "[None (0/22) of normal cervical biopsies, 9% (6/66) of CIN1 lesions, 53% (34/64) of CIN3 lesions, 90% (85/94) of cervical squamous cell carcinomas (SCCs), and 93% (26/28) of cervical adenocarcinomas (AdCAs) demonstrated MAL promoter methylation at both promoter regions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP829095.RAStaN5AjefHaBCHrklV1m6oegr9ACmqIjlZrm36A4c04130_provenance.
NP511930.RAhFcs8J06-1UOAJAtSnW4uBSOx9JN8tMxadQYrpp0ri0130_assertion description "[None (0/22) of normal cervical biopsies, 9% (6/66) of CIN1 lesions, 53% (34/64) of CIN3 lesions, 90% (85/94) of cervical squamous cell carcinomas (SCCs), and 93% (26/28) of cervical adenocarcinomas (AdCAs) demonstrated MAL promoter methylation at both promoter regions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP511930.RAhFcs8J06-1UOAJAtSnW4uBSOx9JN8tMxadQYrpp0ri0130_provenance.
NP783787.RAtu6X2YqtVzcq2jo5LaJMMm93xvUnU87dRSi4GGu8Vfk130_assertion description "[None (0/22) of normal cervical biopsies, 9% (6/66) of CIN1 lesions, 53% (34/64) of CIN3 lesions, 90% (85/94) of cervical squamous cell carcinomas (SCCs), and 93% (26/28) of cervical adenocarcinomas (AdCAs) demonstrated MAL promoter methylation at both promoter regions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP783787.RAtu6X2YqtVzcq2jo5LaJMMm93xvUnU87dRSi4GGu8Vfk130_provenance.
NP451633.RAl3pfLHSLKgh8zt40A3up-hnTSvQ8CxAzoKjG4hMzacU130_assertion description "[None (0/22) of normal cervical biopsies, 9% (6/66) of CIN1 lesions, 53% (34/64) of CIN3 lesions, 90% (85/94) of cervical squamous cell carcinomas (SCCs), and 93% (26/28) of cervical adenocarcinomas (AdCAs) demonstrated MAL promoter methylation at both promoter regions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP451633.RAl3pfLHSLKgh8zt40A3up-hnTSvQ8CxAzoKjG4hMzacU130_provenance.
NP682876.RAdoh5VHv9lDS8jRf0MNnldrv78XdslGhsgBaSW8xFzKc130_assertion description "[None (0/22) of normal cervical biopsies, 9% (6/66) of CIN1 lesions, 53% (34/64) of CIN3 lesions, 90% (85/94) of cervical squamous cell carcinomas (SCCs), and 93% (26/28) of cervical adenocarcinomas (AdCAs) demonstrated MAL promoter methylation at both promoter regions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP682876.RAdoh5VHv9lDS8jRf0MNnldrv78XdslGhsgBaSW8xFzKc130_provenance.
NP912064.RAloGO-_-_rtY0LUQPwOXYXhqIRv_O-MVXj6hChg6fMd4130_assertion description "[None (0/22) of normal cervical biopsies, 9% (6/66) of CIN1 lesions, 53% (34/64) of CIN3 lesions, 90% (85/94) of cervical squamous cell carcinomas (SCCs), and 93% (26/28) of cervical adenocarcinomas (AdCAs) demonstrated MAL promoter methylation at both promoter regions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP912064.RAloGO-_-_rtY0LUQPwOXYXhqIRv_O-MVXj6hChg6fMd4130_provenance.
NP651535.RA4d-Qxo2Z_SQ0nrNtNudRe8ygW5kSaq-rVCJ7CBiFpcE130_assertion description "[None (0/22) of normal cervical biopsies, 9% (6/66) of CIN1 lesions, 53% (34/64) of CIN3 lesions, 90% (85/94) of cervical squamous cell carcinomas (SCCs), and 93% (26/28) of cervical adenocarcinomas (AdCAs) demonstrated MAL promoter methylation at both promoter regions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP651535.RA4d-Qxo2Z_SQ0nrNtNudRe8ygW5kSaq-rVCJ7CBiFpcE130_provenance.
assertion description "[None (0/22) of normal cervical biopsies, 9% (6/66) of CIN1 lesions, 53% (34/64) of CIN3 lesions, 90% (85/94) of cervical squamous cell carcinomas (SCCs), and 93% (26/28) of cervical adenocarcinomas (AdCAs) demonstrated MAL promoter methylation at both promoter regions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
NP756063.RAcBhaLpcJsGZk0rgCQx4YkZ83DxfSfdXIdYn0ju4i6Cg130_assertion description "[None (0/22) of normal cervical biopsies, 9% (6/66) of CIN1 lesions, 53% (34/64) of CIN3 lesions, 90% (85/94) of cervical squamous cell carcinomas (SCCs), and 93% (26/28) of cervical adenocarcinomas (AdCAs) demonstrated MAL promoter methylation at both promoter regions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP756063.RAcBhaLpcJsGZk0rgCQx4YkZ83DxfSfdXIdYn0ju4i6Cg130_provenance.